Evogene Ltd
EVGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.07M
Close$
Share Statistics
| Market cap | $6.07 Million |
|---|---|
| Enterprise Value | $-416,140.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.08 |
| Beta | 0.8 |
| Outstanding Shares | 9,738,434 |
Return
| Return on Equity | 539.25% |
|---|---|
| Return on Assets | -76.47% |
| Return on Invested Capital | -172.04% |
Valuation & Multiples
| P/E Ratio | -0.58 |
|---|---|
| PEG | -0.29 |
| Price to Sales | - |
| Price to Book Ratio | 0.61 |
| Enterprise Value to Revenue | -0.08 |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -4.93 |
| Debt to Equity | -0.81 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 27, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$350,000
Average shareholder expectationNext Earnings Call
Expected Date
August 26, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$325,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Evogene Ltd
CEO: Ofer Haviv Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, I...